Bayer's 70-Euro Question: A Missouri Courtroom, an FDA Green Light, and Two Very Different Clocks
Published on 09/12/2026 at 13:21 | Editorial boerse-global.de
Bayer shareholders are being asked to hold two contradictory ideas at once. On one side sits a freshly accelerated US approval for a lung-cancer drug and a pipeline that Barclays thinks is worth 70 euros a share. On the other sits a St. Louis courtroom where a judge will soon decide whether a $7.25 billion settlement can finally bury the glyphosate litigation — or merely reshuffle it.
The stock closed Friday at EUR 48.19, down 0.6% on the day, roughly 11% below its 52-week high of EUR 53.86 and a world away from the 70-euro target Barclays reaffirmed on Tuesday, lifting its estimate from EUR 60 while keeping an Overweight rating. That gap is the whole story: either the oncology pipeline and the legal endgame converge on something resembling the analysts' math, or the market's caution proves better calibrated than the sell-side's optimism.
What Bayer Actually Won This Week
The FDA granted accelerated approval to sevabertinib as a first-line treatment for certain forms of non-small cell lung cancer — a milestone Bayer itself flagged for its oncology portfolio. It is a regulatory victory, not a commercial one. Accelerated approvals come with conditions, and the real revenue question hinges on reimbursement decisions and how readily physicians write the prescription, processes that can stretch over years. No sales data exists yet.
Bayer also kicked off a Phase II trial for an investigational GIRK4 inhibitor targeting atrial fibrillation, an early but strategically meaningful push into a new indication. Separately, the company struck a commercial partnership with Neste to scale winter rapeseed newgold jointly — a quieter piece of the puzzle, but one that fits the agricultural narrative.
Those headlines land against a stock that has climbed 30% year-to-date but has lost momentum recently, slipping 1.3% over the past week. Its RSI sits at 47.4 — neutral territory, neither overbought nor oversold, which reads as consolidation rather than conviction in either direction.
Should investors sell immediately? Or is it worth buying Bayer?
The Legal Clock Ticking Toward September 14
Monday, September 14 brings the date that may matter more than any pipeline catalyst this quarter. Judge Timothy Boyer in Missouri will hear objections to the $7.25 billion class settlement designed to resolve roughly 65,000 outstanding Roundup claims in the US. A final ruling is not expected that day.
The settlement would supersede earlier arrangements — Bayer already spent about $10 billion on a 2020 settlement that failed to quiet the litigation. Payouts under the new deal would range from $10,000 to $165,000 per case, calibrated to non-Hodgkin lymphoma diagnoses. The 8th Circuit Court of Appeals rejected objections to the settlement in late August, which helps. Whether Boyer signs off determines whether Bayer can credibly cap its glyphosate risk reserve — or faces fresh waves of claims.
Two developments lean Bayer's way. In June, the US Supreme Court ruled 7-2 in the Durnell case that federal law (FIFRA) preempts state-level failure-to-warn claims, a precedent that could make future suits harder to bring. And the EPA has signaled an updated glyphosate assessment for late 2026; if it holds to its 2017 position that the ingredient is not carcinogenic, that would reinforce Bayer's defense.
The bear case rests on sheer volume. With 65,000 open cases, any procedural delay is expensive — and the IARC's 2015 classification of glyphosate as "probably carcinogenic" still anchors many complaints, meaning the scientific dispute is far from settled. If Boyer rejects parts of the deal or confirmation stalls on further objections, new rounds before higher courts beckon. A sharper-than-expected EPA verdict in 2026 could reignite litigation rather than end it. The stock trades just under its 50-day moving average of EUR 48.57 — a sign the market is pricing Monday with caution.
Two Engines, Two Speeds
The bull case for Bayer requires both clocks to cooperate. If sevabertinib achieves commercial traction, oncology becomes a new growth pillar that takes pressure off the lower-margin agricultural business. Progress on Crop Science's ten-blockbuster plan — Reuters reports two products already marketed and roughly EUR 400 million in cost savings realized — would round out the picture. Confirm the mid-term margin targets, an EBITDA margin before special items in the mid-20% range by the end of the decade, and Barclays' 70-euro target starts to look fundamentally anchored. The shares have already traveled far from their 52-week low of EUR 25.78, up 87% from that trough roughly ten months ago.
The bear case is about timing. Accelerated approvals carry obligations, and reimbursement plus prescribing behavior decide the revenue contribution — processes measured in years, not quarters. The GIRK4 inhibitor is in early-stage testing with no guarantee of success. If the promised Crop Science savings prove harder to extract than advertised, group margins suffer. And the market's recent hesitation — the 1.3% weekly decline, the neutral RSI — suggests analysts' enthusiasm is not being swallowed whole.
What to Watch
As long as Bayer stays on schedule with its oncology build-out and the Crop Science blockbuster plan, the medium-term uptrend since that low ten months ago looks defensible. If approval or commercialization steps slip, or if cost-cutting at Crop Science stalls, the distance between the 70-euro targets and the actual share price is more likely to widen than close.
Near term, the concrete tests are clear: the September 14 hearing in St. Louis, followed by the EPA's glyphosate reassessment due by the end of 2026. On the pipeline side, sevabertinib's commercial trajectory and Crop Science progress updates are the markers to track. Until hard sales figures arrive, the valuation question stays open — and so does the decision facing investors: run ahead of the analysts, or wait for operational proof.
Ad
Bayer Stock: New Analysis - 12 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
